Xenon Pharmaceuticals Inc（XENE）の財務XENEXenon Pharmaceuticals Inc

Evaluating the bottom line, Xenon Pharmaceuticals Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -43.62%, provide a clear picture of how effectively XENE converts its operational activities into shareholder value.

In the context of the broader market, XENE competes directly with industry leaders such as AMLX and ACAD. With a market capitalization of $3.42B, it holds a significant position in the sector. When comparing efficiency, XENE's gross margin of N/A stands against AMLX's N/A and ACAD's 90.81%. Such benchmarking helps identify whether Xenon Pharmaceuticals Inc. is trading at a premium or discount relative to its financial performance.

Xenon has posted significant net losses, with Q2 2026 showing a net loss of $110.7 million and no revenue generated in recent quarters. The gross margin is currently at 0%, reflecting the lack of product sales.